deltatrials
Completed PHASE2 NCT00002239

A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

A Controlled Phase 2 Trial Assessing Three Doses of T-20 in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz in HIV-1 Infected Adults

Sponsor: Hoffmann-La Roche

Conditions HIV Infections
Interventions Abacavir sulfate Amprenavir Efavirenz Enfuvirtide Ritonavir
Updated 6 times since 2017 Last updated: Nov 14, 2005 Started: May 31, 1999

A PHASE2 clinical study on HIV Infections, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 6 data snapshots since 1999. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

May 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoffmann-La Roche
  • Trimeris
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Altamonte Springs, United States, Atlanta, United States, Austin, United States, Baltimore, United States, Beverly Hills, United States, Durham, United States, Fort Lauderdale, United States, Los Angeles, United States, New York, United States, Palm Springs, United States and 7 more location s